Berlin’s testing strategy
This web page provides general information on measures which have either been planned or implemented as part of Berlin’s testing strategy.
You are here:
The Senate of Berlin has commissioned Charité – Universitätsmedizin Berlin and Vivantes – Netzwerk für Gesundheit GmbH to design the concept for and coordinate the implementation of Berlin’s testing strategy. We hope to complement the existing testing protocol which is aimed at symptomatic individuals. The testing of symptomatic individuals falls under the remit of our public health colleagues and forms the foundation of our fight against the infection.
Berlin’s testing strategy complements the existing protocol by extending testing to specific groups of individuals who are (still) asymptomatic.
The aim of this joint testing strategy is to ‘enable a return to normal life by restoring people’s health and Berlin’s economic and social order’. What we mean by this is that a smart testing approach can help to identify infections early, enabling us to better control the pandemic and support a gradual return to normal life.
What is our approach?
Taking into consideration a range of scientific issues, we started by defining population groups which would be placed at the center of the testing strategy, either due to their increased risk of developing severe symptoms or because of their association with an increased risk of transmission. This includes individuals who work in educational, care or medical facilities and individuals from other sectors with increased exposure.
Please see below for more information on the working groups (AGs) involved, which will focus on the general population, educational facilities, care facilities and hospitals.
This web page provides general information on measures which are either planned or have been implemented as part of Berlin’s testing strategy.
Please note that the testing of individuals with symptoms indicative of COVID-19 (as per RKI criteria) is being delivered via the public health service and private medical practices, and is entirely independent of the specific objectives, premises and issues underpinning individual AGs.
The aim of Berlin’s testing strategy is to offer a science- and evidence-based approach which enables the early identification of potential clusters or outbreaks. This will produce the data necessary to guide and assist decision-makers from politics and the public health service (ÖGD). Charité is responsible for developing the concept behind the testing strategy. Its implementation will be the responsibility of Charité in consultation with the relevant Senate Departments and the ÖGD.
The concept reflects current conditions and will be adapted as the situation develops. The testing strategy comprises a range of testing options for asymptomatic individuals. All of these are offered on a purely voluntary basis.